The board (the " Board ") of directors (" Directors ") of SinoMab BioScience Limited (the "Company") announced that in order to pursue his other personal and business commitments, Mr. Chang LIU ("Mr. Liu") has tendered his resignation as a non-executive Director with effect from 23 December 2019. The Board further announced the following appointments: (1) Mr. Jing QIANG ("Mr. Qiang") has been appointed as an executive Director of the Company; (2) Mr. Xun DONG ("Mr. Dong") has been appointed as a non-executive Director of the Company; and (3) Mr. George William Hunter CAUTHERLEY ("Mr. Cautherley") has been appointed as an independent non-executive Director of the Company. Mr. Qiang, aged 37, has served as the president of the Company since March 2018 and is primarily responsible for strategic planning and investments. Mr. Dong, aged 45, has over 20 years of experience in the pharmaceutical industry. Between 1996 and 2004, Mr. Dong worked for Yunnan Baiyao Group Co. Ltd. ("Baiyao Group"). Mr. Cautherley, aged 77, has 55 years of experience of distributing a wide range of medical products and pharmaceuticals in Hong Kong, China and South East Asian countries and for the past 40 years through companies of which he has been CEO and substantive shareholder.